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II. Research Team

I. Introduction
There are numerous books about Attention-Deficit/Hyperactivity Disorder
(ADHD) on the market. These books range from being very nontechnical, geared
towards elementary educators and parents, to highly technical, geared towards
medical and mental health professionals. To complicate matters further, the
manner in which ADHD is defined and diagnosed has recently changed with the
release of the DSM-V in 2013, which makes even relatively recent texts out-ofdate. This Creative Inquiry project involves research into the most recent data
on the neurochemistry behind what causes ADHD and comorbid conditions, as
well as the neurochemistry of how drugs used to treat these conditions work to
affect patient mental health. The goal of this project is to write and publish a
book that begins with simple descriptions of these processes and builds to
more technical language, providing parents and teachers with the ability to
become experts in ADHD without a preexisting background in science.

IV. Comorbid Conditions
The most common statistics indicate that about 65% of ADHD patients have at least one comorbid
condition. The graph below displays the frequencies of the more commonly observed conditions in
ADHD patients.
Comorbid conditions lead to an increase in
the complexity of ADHD, impacting the
symptoms, diagnosis, and prognosis of
ADHD. In addition, comorbid conditions
increase the difficulty of treatment
selection. For the patient, comorbid
conditions increase the morbidity and
disease burden of ADHD and also may
affect patient compliance, leading to
further difficulties in treatment.
Analyzing the true correlation/coincidence
of ADHD and other conditions is
complicated by the additional influence of
socioeconomic standing, risk factors in
pregnancy (see box VIII), etc.

VII. Genetics
Genetic factors and biochemical abnormalities play considerably large roles in the etiology of
ADHD. Several molecular genetics studies have demonstrated that deficiencies in the
serotonergic and dopaminergic systems (see box V) are associated with brain abnormalities
that cause major symptoms of ADHD. Two dopamine candidate genes have been identified
through numerous genetic studies and show a strong association with the neuropsychiatric
disorder ADHD when expressed, specifically the dopamine transporter gene (DAT1) and the
dopamine receptor gene (DRD4). Impaired dopamine transmission has a strong correlation
with typical ADHD symptoms such as hyperactivity, inattention, and impulsivity. There is
currently substantial evidence that links several genes coding for DRD4, DAT1, 5-HTT, DRD5,
and HTR1B to the etiology of ADHD.
Dopamine Genes
• This DRD4 gene is expressed in the frontal lobe region of the brain and is involved in the
dopaminergic system (see box V ) and affects functions like language processing, memory,
and attention.
•

The association between a 48 base-pair repeat polymorphism of exon III of the DRD4
gene and ADHD is the most consistent and replicated molecular genetic ﬁnding in ADHD.

III. ADHD in DSM-V: Definition and Diagnosis
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V. Neurochemistry of ADHD
Dopamine plays a role in memory and
reinforcement (see image to the right) but in
ADHD patients, Dopamine Transmission levels are
found to be decreased, causing inattention and
difficulty in memory formation.
Norepinephrine is also involved in cognition and
behavior, but the receptors for norepinephrine are
much less efficient in ADHD patients’ brains than
healthy brains (see image to the left). This leads to
poor neuron function, leading to impulsivity and
inattention.
Serotonin is a key component in controlling
impulsivity and the ADHD brain has a decreased
number of serotonin receptors (see image to the
right), leading to hyperactivity and impulsivity.

The manner in which ADHD is defined and diagnosed has recently undergone significant change
with the release of the new Diagnosis and Statistics Manual V in 2013. One significant change is that
the condition known as “ADD” is no longer a diagnosis that is made. ADHD is now the recognized
term for the condition. ADHD can present as one of three subconditions on the basis of which
particular symptoms predominate in the patient: Predominantly inattentive, predominantly
hyperactivity/impulsive, or combined type. From there the disorder can be classified as either mild,
moderate, or severe.
An essential feature of diagnosis is the persistence of inattention and/or hyperactivity-impulsivity
that interferes with functioning of the patient or their development. Furthermore, symptoms and
manifestations of the disorder must be present in multiple settings, such as home and school, work,
etc.
Inattention is viewed as lack of persistence, inability to concentrate on a set task, difficulty with
sustaining focus, and being disorganized.
Hyperactivity is viewed as excessive motor activity when it is deemed inappropriate, or excessive
fidgeting, tapping or talkativeness.
Impulsivity is known as actions taken or decisions made without forethought that has a high chance
of causing harm to the individual.

VI. Treatment Options

There are both medicinal and non-medicinal treatment options for ADHD, with medicinal options
being much more common and offering much more consistent results.
FDA approved medications for ADHD are broken down into stimulants and non-stimulants:
Stimulants:
• Methylphenidate (Ritalin)- The most common psychoactive stimulant prescribed, it is believed to
work by inhibiting the dopamine transporter (see box V, upper figure) in the presynaptic cell
membrane, blocking its reuptake, causing an increase of dopamine in the synapse
• Amphetamine (Adderall)- Believed to work through increasing levels of neurotransmitters,
including dopamine and norepinephrine, in the synapse by causing the release of newly
synthesized cytosolic dopamine from the nerve terminal
Non-stimulants:
• Atomoxetine (Strattera)- a specific presynaptic inhibitor of norepinephrine reuptake (see box V,
middle figure), increasing the levels of the neurotransmitter in the synapse
• α-2 Agonists (Kapvay and Intuniv)- inhibit the release of the norepinephrine neurotransmitter
(see box V, middle figure), which decreases the body’s state of arousal
Non-medicinal options:
• Behavioral therapy, cognitive therapy, neurofeedback, modifying diet/nutrition, and increasing
exercise

VIII. Pregnancy and Risk Factors
ADHD can be caused by a variety of genetic and environmental factors, including
prenatal factors to which the fetus is exposed before birth. Recent studies have
concluded that nicotine, alcohol, and mercury exposure in utero may lead to
development of ADHD later in life. It is important to note that these studies have
shown a correlation, but not necessarily a
causative effect between these substances
and the onset of ADHD. It is possible that
these substances are part of larger
environmental and genetic (See box VII)
components and do not impair fetal
development on their own. Either way, it is
essential for mothers to be informed on these
issues and how their actions can affect their
child’s mental development. This appears to
be an area requiring significant additional
research.

IX. Conclusions
The recent changes with respect to how professionals define and diagnose the
condition of ADHD were the primary motivation for this study. It is important to
evaluate the most up-to-date information related to ADHD across a range of
scientific disciplines and to cast all the previous studies in light of the new
definitions. Although we have only been exploring available scientific data for a
about two months for this project, a notable challenge we have faced is the
inconsistency of study parameters and the complexities involved in analyzing studies
on human subjects to extract meaningful, clear conclusions. We hope to continue a
detailed analysis of available original research studies in an effort to reveal clear
understanding of the science behind ADHD and treatment options for so that nonexperts can make educated assessments related to the condition.
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